Natera president Solomon Moshkevich sells over $5.9m in shares
Natera, Inc. (NASDAQ:NTRA) President Solomon Moshkevich sold 18,160 shares totaling $5.92 million over two days. Shares were sold at prices ranging from $319.7582 to $326.894, with sales conducted under a Rule 10b5-1 trading plan. Natera's stock is near its 52-week high, up 97% over the past year, and reported strong Q2 revenue of $753 million, exceeding expectations. The company raised its full-year revenue guidance, citing record test volumes and improved margins. According to InvestingPro, th
How this was made
The 30-second read
Why it matters
The insider sale occurs amid a bullish backdrop, creating a mixed signal for traders.
Market read
While Natera's earnings beat fuels upside, the sizable insider sale adds short‑term downside risk.
What to watch
The proceeds were used to cover tax obligations on RSU vesting, reducing the negative signal.
Background
Natera reported strong Q2 results and raised full‑year guidance, pushing the stock near its 52‑week high.
Ticker impact
SEC Form 4 shows President Solomon Moshkevich sold 18,160 shares for $5.92 million over Sep 1‑2, 2026.
possible modest dip in near‑term trading as market digests the sale
Sale size (~$6 M) is material for a mid‑cap biotech; executed under a 10b5‑1 plan but still noteworthy for traders.
Market effects
Insider sale may prompt scrutiny of other biotech executives' holdings.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond Natera shareholders.
Counterpoint
The sale was pre‑planned under a 10b5‑1 plan and may not reflect negative sentiment.
Key entities
- executiveSolomon Moshkevich
President of Clinical Diagnostics at Natera
- companyNatera, Inc.
Genetic testing and diagnostics firm (NASDAQ:NTRA)
